US2024033229A1PendingUtilityA1

Use of cannabinoids in the treatment of epilepsy

78
Assignee: GW RES LTDPriority: Mar 31, 2016Filed: Feb 16, 2023Published: Feb 1, 2024
Est. expiryMar 31, 2036(~9.7 yrs left)· nominal 20-yr term from priority
Inventors:Geoffrey GuyStephen WrightAlice MeadAnne Comi
A61K 36/185A61K 36/3482A61K 31/658A61K 31/05A61K 31/352A61K 45/06A61P 25/08A61K 31/165A61K 31/22A61K 31/27A61K 31/357A61K 31/4015A61K 31/55A61K 31/5513A61K 36/00
78
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

Claims

exact text as granted — not AI-modified
1 . A method of treating Sturge Weber syndrome in a subject, comprising administering to the subject a therapeutically effective amount of cannabidiol (CBD) drug substance, wherein the CBD drug substance comprises at least 98% (w/w) CBD. 
     
     
         2 . The method of  claim 1 , wherein the treating comprises treating seizures in a subject having Sturge Weber syndrome. 
     
     
         3 . The method of  claim 1 , wherein the treating comprises treating non-seizure symptoms in a subject having Sturge Weber syndrome. 
     
     
         4 . The method of  claim 3 , wherein the non-seizure symptoms are one or more of mood, behavior, cognitive function and general quality of life. 
     
     
         5 . The method of  claim 1 , wherein the drug substance comprises less than 0.15% tetrahydrocannabinol (THC). 
     
     
         6 . The method of  claim 1 , wherein the drug substance further comprises up to 1% cannabidivarin (CBDV). 
     
     
         7 . The method of  claim 1 , wherein the drug substance further comprises between 0.1 and 1.0% CBDV. 
     
     
         8 . The method of  claim 1 , wherein the CBD is present as a synthetic compound. 
     
     
         9 . The method of  claim 1 , wherein the dose of CBD is about 10 mg/kg/day. 
     
     
         10 . The method of  claim 1 , wherein the subject is a child or young adult. 
     
     
         11 . The method of  claim 1 , wherein the dose of CBD ranges from about 5 mg/kg/day to about 25 mg/kg/day. 
     
     
         12 . The method of  claim 1 , wherein the dose of CBD is about 20 mg/kg/day. 
     
     
         13 . The method of  claim 1 , wherein the dose of CBD is about 25 mg/kg/day. 
     
     
         14 . The method of  claim 1 , wherein the CBD drug substance is a highly purified extract of  cannabis.    
     
     
         15 . The method of  claim 2 , wherein the dose of CBD ranges from about 5 mg/kg/day to about 25 mg/kg/day. 
     
     
         16 . The method of  claim 2 , wherein the dose of CBD is about 10 mg/kg/day. 
     
     
         17 . The method of  claim 2 , wherein the dose of CBD is about 20 mg/kg/day. 
     
     
         18 . The method of  claim 2 , wherein the dose of CBD is about 25 mg/kg/day. 
     
     
         19 . The method of  claim 3 , wherein the dose of CBD ranges from about 5 mg/kg/day to about 25 mg/kg/day. 
     
     
         20 . The method of  claim 3 , wherein the dose of CBD is about 10 mg/kg/day. 
     
     
         21 . (canceled) 
     
     
         22 . (canceled)

Join the waitlist — get patent alerts

Track US2024033229A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.